- Home
- CET vs INVA Comparison
CET vs INVA Comparison
Compare CET & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CET | INVA |
|---|---|---|
| Founded | 1929 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CET | INVA |
|---|---|---|
| Price | $53.36 | $23.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 38.9K | ★ 513.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 2.22 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | N/A | $8.95 |
| Revenue Next Year | N/A | $12.65 |
| P/E Ratio | ★ $6.93 | $10.20 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $45.77 | $16.52 |
| 52 Week High | $54.28 | $25.15 |
Technical Indicators
Market Signals| Indicator | CET | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 58.03 | 50.49 |
| Support Level | $50.64 | $19.30 |
| Resistance Level | $53.88 | $24.80 |
| Average True Range (ATR) | 0.70 | 0.67 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 54.68 | 50.00 |
Price Performance
Historical ComparisonAbout CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.